Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103854" target="_blank" >RIV/00843989:_____/13:E0103854 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1056/NEJMoa1306638" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1306638</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1306638" target="_blank" >10.1056/NEJMoa1306638</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

Popis výsledku v původním jazyce

Background:Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. Methods:In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.Results:A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which

Název v anglickém jazyce

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

Popis výsledku anglicky

Background:Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. Methods:In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.Results:A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

369

Číslo periodika v rámci svazku

n. 15

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

"p. 1406-1415"

Kód UT WoS článku

000325431500008

EID výsledku v databázi Scopus

—